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Mesoangioblasts (MABs) are vessel-associated stem cells that express pericyte marker genes and participate in skeletal muscle
regeneration. Molecular circuits that regulate the myogenic commitment of MABs are still poorly characterized. The critical role of
bone morphogenetic protein (BMP) signalling during proliferation and differentiation of adult myogenic precursors, such as satellite
cells, has recently been established.We evaluatedwhether BMP signalling impacts on themyogenic potential of embryonic and adult
MABs both in vitro and in vivo. Addition of BMP inhibited MAB myogenic differentiation, whereas interference with the interactions
between BMPs and receptor complexes induced differentiation. Similarly, siRNA-mediated knockdown of Smad8 in Smad1/5-null
MABs or inhibition of SMAD1/5/8 phosphorylation with Dorsomorphin (DM) also improved myogenic differentiation, demonstrating
a novel role of SMAD8. Moreover, using a transgenic mouse model of Smad8 deletion, we demonstrated that the absence of SMAD8
protein improved MAB myogenic differentiation. Furthermore, once injected into a-Sarcoglycan (Sgca)-null muscles, DM-treated
MABs were more efficacious to restore a-sarcoglycan (aSG) protein levels and re-establish functional muscle properties. Similarly,
in acute muscle damage, DM-treated MABs displayed a better myogenic potential compared with BMP-treated and untreated cells.
Finally, SMADs also control the myogenic commitment of human MABs (hMABs). BMP signalling antagonists are therefore novel
candidates to improve the therapeutic effects of hMABs.
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Introduction
Murine and human mesoangioblasts (MABs) are pericyte-
derived cells and represent an intriguing source of multipotent
stem cells located in the adult muscle tissue around small
vessels (Dellavalle et al., 2007), or in the embryo around the
dorsal aorta (Tonlorenzi et al., 2007). These pericytes can be pro-
spectively isolated from freshly dissociated alkaline phosphatase
(AP+) cells of both mouse and human samples (Quattrocelli
et al., 2012) and proliferate in vitro under specific culture condi-
tions. When transplanted into animal models for muscular dystro-
phies (MDs), MABs have been demonstrated to colonize host
muscles and revert the dystrophic phenotype (Sampaolesi et al.,
2003, 2006; Dellavalle et al., 2007; Chun et al., 2013). Indeed,
these muscle progenitors, which intrinsically differ from satellite
cells (SCs), display trans-endothelial migration when systemically
injected (Tedesco and Cossu, 2012) and are currently tested in a
phase-1 clinical study in Duchenne Muscular Dystrophy (DMD)
patients (EudraCT #2011-000176-33).
The mechanisms inducing MABs to differentiate towards
skeletal muscles are still poorly defined. Recently, we showed
that Delta-like ligand 1 (Dll1)-activated NOTCH1 and downstream
MEF2C support MAB myogenic commitment in vitro and in vivo
(Quattrocelli et al., 2014). However, other signalling pathways
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involved in pathological processes in MDs, such as fibrosis, inflam-
mation, and regeneration, still need to be elucidated. Nuclear
factor-kB (NF-kB) and transforming growth factor-b1 (TGFb1) path-
ways have already been connected to dystrophic muscle degener-
ation in DMD patients and mouse models (Bernasconi et al., 1995;
Chen et al., 2005; Acharyya et al., 2007; Christov et al., 2007; Cohn
et al., 2007).
Here, we investigate whether bone morphogenetic protein
(BMP)–SMAD signalling could play a role in regulating MAB myo-
genic capacity. BMPs are secreted factors able to activate specific
BMP receptor complexes (BMPRs) that phosphorylate intracellular
SMAD effector proteins (i.e. SMAD1, SMAD5, SMAD8), as well
as non-SMAD signalling-dependent protein kinases (Feng and
Derynck, 2005). After translocation to the nucleus, activated
SMADs bind to DNA and regulate specific target genes, including
the Inhibitor of differentiation/DNA binding (ID) genes (Katagiri
et al., 2002). Indeed, IDs sequester and inactivate ubiquitous
E-box binding proteins thereby hampering their binding with
tissue-specific E-family transcription factors such as MyoD and
myogenin, which are necessary for the entire muscle differentiation
programme (Jen et al., 1992). Previous studies have demonstrated
that the receptor-mediated phosphorylation of SMAD1/5/8
(P-SMAD1/5/8) guides the stemness of SCs and modulates their
differentiation (Ono et al., 2011). Furthermore, the inhibition of
BMP signalling in adult healthy muscles is responsible for muscle
atrophy, influencing a specific ubiquitin ligase (Sartori et al.,2013).
Here, using different approaches, we demonstrate how the inhib-
ition of SMAD-mediated BMP pathway promotes the contribution
of MABs to the formation of myotubes. Surprisingly, genetic inhib-
ition of Smad1/5 did not affect the myotube formation in vitro.
However, additional silencing ofSmad8 resulted in enhanced myo-
genic differentiation. The injection in dystrophic mice of MABs with
reduced SMAD signalling improved the functional recovery of
the dystrophic phenotype. We also found that MABs from both
embryo and adult mice, as well as from human, act similarly.
Notably, we provide evidence that the myogenic commitment of
human MABs (hMABs) is under the control of SMAD1/5/8; perturb-
ation of this control has an impact on human MAB myogenic differ-
entiation ability.
Results
Murine MAB growth and differentiation
Adult MABs (aMABs) carrying GFP were co-cultured with C2C12
cells and induced to differentiate by serum starvation. After 5 days
of differentiation, double-positive GFP+/ MyHC+ myotubes were
detected by immunofluorescence (IF) analysis (Figure 1A and B).
The growth curves of GFP+ primary murine MABs and C2C12 murine
myogenic cells are shown in Figure 1C and H. The differentiation
was confirmed by WB analysis (Figure 1D), where MyHC was again
detected on Day 5 of differentiation. The absence of MyHC in aMAB
cultures confirmed that adult murine MABs do not spontaneously
undergomyogenicdifferentiation(Quattrocellietal.,2014).Thequan-
tification of the amount of MyHC reported an increment in co-culture
conditions with respect to C2C12 cells (Figure 1E). Interestingly, this
improvement in differentiation was also observed in co-culture
experiments with embryonic MABs (eMABs, Figure 1F–J) and dys-
trophicMABs(dMABs),anaberrantmodel ofcardiac mesoangioblasts
isolated from b-Sarcoglycan-null mice (dMABs; Crippa et al., 2011)
(Supplementary Figure S1). Altogether, these data confirm that
murine MABs improve the myogenic differentiation of C2C12 cells.
BMP signalling regulates MAB differentiation
BMP signalling is relevant to SCs maintenance (Ono et al., 2011)
and its importance for eMABs has been suggested in a previous
report, wherein Noggin, a secreted inhibitor of BMP ligands, was
shown to promote myotube differentiation (Ugarte et al., 2012). IF
analyses of GFP+ aMABs co-cultured with C2C12 cells showed
nuclear expression of both P-SMAD1/5/8 and ID proteins in
GFP+ aMABs on Day 0 (Figure 2A). On Day 3 of differentiation
(Figure 2B), a reduction of P-SMAD1/5/8 and ID nuclear staining
was observed, mainly in GFP+ multinucleated cells, suggesting
that a decreased BMP signalling is necessary to promote myotube
formation. These results were verified by WB analysis (Figure 2C
and Supplementary Figure S2A, B). Similar data were confirmed in
co-cultures of eMABs, where the levels of P-SMAD1/5/8 and ID pro-
teins were almost completely decreased in eMABs when cells were
co-cultured in differentiation medium for 3 days (Figure 2D–F).
Taken together, these results support that BMPs and downstream
BMP–SMAD signalling maintain the stemness of both embryonic
and adult MABs, and that inhibition of this pathway is required to
trigger myotube formation.
Gain and loss-of-function studies
We reported that aMABs are not able to form spontaneously myo-
tubes and the permanent treatment with Noggin, an acknowledged
BMP antagonist (Reshef et al.,1998; Linker et al.,2003; Tzahor et al.,
2003), or Dorsomorphin (DM), a synthetic inhibitor of type I BMP
receptor complex (Hao et al., 2008; Yu et al., 2008) cannot sort
any myogenic effects (Figure 3A and B). However, BMP4 was able
to induce MAB proliferation as documented by the increased
number of Ki67-positive cells (Figure 3B and E). To understand the
impact of BMP signalling on the differentiation of MABs into myo-
tubes, we transiently (48 h) treated co-cultures of C2C12 cells and
aMABs with BMP4 (Figure 3C and F) or eMABs (Figure 3D and G)
(Katagiri et al.,1997; Dahlqvist et al.,2003). In parallel, we transient-
ly treated co-cultures with Noggin or DM. After 5 days of myogenic
differentiation, no GFP+/MyHC+ myotubes were present in any of
the co-cultures exposed to BMP4 (Figure 3C and D). In contrast,
co-cultures treated with Noggin or DM showed high presence of
double-positive myotubes, indicating that blockade of BMP signal-
ling has a strong differentiation-inducing effect (Figure 3C and D).
Finally, the calculated fusion index in the chimeric myotubes con-
firmed that no differentiation was detected when the co-cultures
were pre-treated with BMP4, whereas a significant increment
was noticed in co-cultures treated with Noggin or DM (Figure 3F, G
and Supplementary Figure S2C–E). The co-culture experiments
in which MABs alone were exposed to BMP4, Noggin, or DM
(Supplementary Figure S3A–C), and in which differentiation was
induced by adding C2C12 cells after treatment, focused on addres-
sing the critical role of BMP signalling in MAB myogenic commitment.
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Moreover, DM administration under differentiating conditions also
resulted in increased myotube formation (Supplementary Figure
S4A–D). These results highlight the importance of BMP signalling
in maintaining MAB stemness (Supplementary Figure S5A–C) and
the necessity of inhibition of this BMP effect (Supplementary Figure
S5D and E) in order to proceed further along the myogenic route.
Smad1/5 depletion is not sufficient to improve myogenic
differentiation
Mouse embryos deficient in type I receptor ALK-1 (activin
receptor-like kinase-1, known to bind primarily BMP, and also
TGFb, on endothelial cells) exhibit delayeddifferentiationofvascular
smooth muscle cells with their consequent failure to localize to peri-
vascular regions (Oh et al., 2000). Moreover, Smad5-knockout
embryos have enlarged blood vessels with decreased numbers of
vascular smooth muscle cells, and these embryos die around
E10.5–11.5 due to defects in the circulatory system (Chang et al.,
1999; Yang et al., 1999; Goumans and Mummery, 2000). The differ-
ence in severity of the phenotypes between ligand, receptor, and
Smad-deficient mice suggests that, in the case of BMPs in particular,
other receptors and ligands may partially compensate for the loss of
one protein (Pangas et al., 2008; Beets et al., 2013). In order to
define the role of different BMP-SMADs in pericytes, we investigate
the differentiation ability of MABs isolated from adult mice and
Figure 1 Myogenic differentiation of adult mesoangioblasts (aMABs) and embryonic mesoangioblasts (eMABs). (A) Merged images (phase-
contrast and GFP signal) of GFP+ aMABs co-cultured with C2C12 cells (1:1 at the start) in differentiation medium on Day 5. (B) IF for MyHC and
GFP (respectively in red and green). Nuclei were stained in blue with Hoechst. (C) Growth curves of aMAB (grey line) and C2C12 (black line) cell
cultures under growing conditions, respectively. (D) WB for MyHC, GFP, and tubulin (TUB) in C2C12, aMABs, and co-cultures (coc) of aMABs
and C2C12 (1:1) on Day 0 and 5 of differentiation. (E) Quantification for the levels of MyHC normalized by TUB in C2C12, aMABs, and co-cultures
on Day 5 of differentiation. (F) Merged images (phase-contrast and GFP signal) of GFP+ eMABs co-cultured with C2C12 (1:1) in differentiation
medium on Day 5. (G) IF analysis for MyHC and GFP (respectively in red and green). Nuclei were stained in blue with Hoechst. (H) Growth
curves of eMAB and C2C12 cultures under growing conditions, respectively. (I) WB for MyHC, GFP, tubulin (TUB) in C2C12, eMABs, and co-cultures
of eMABS and C2C12 (1:1) on Day 0 and 5 of differentiation. (J) Quantification for the levels of MyHC normalized by TUB in C2C12, eMABs, and
co-cultures on Day 5 of differentiation. Data are representative of three independent experiments and values are expressed as mean+SD;
*P, 0.05, ***P, 0.001 vs. C2C12. Scale bar, 500 mm.
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embryos deficient for Smad1/5 into SM22-positive cells (see
Materials and methods and Supplementary Figure S6A). The
growth rate of Smad1/5-null MABs was not significantly different
from littermate control MABs (data not shown). However, a residual
BMP–P-SMAD signal was detected by WB analysis in Smad1/5-null
aMABs (Figure 4A and B) and eMABs (Figure 4D and E) although not
detectable by IF analysis. A significant increase in the levels of
SMAD8 protein (by WB, see Figure 4B and E) and mRNA
(Figure 4C) was detected in the Smad1/5-null aMABs.
We then tested the differentiation ability of Smad1/5-null MABs
in co-cultures with C2C12 cells (Figure 4F and G). The number of
double-positive myotubes was not changed when using either
Smad1/5-null aMABs or Smad1/5-null eMAB co-cultures com-
pared with WT aMABs and eMABs (Figure 4H). Hence, the deletion
of Smad1/5, often referred to as the major BMP-SMADs, is not suf-
ficient to improve myotube differentiation of murine MABs. This
prompted us to investigate in more detail the possible functions
of SMAD8.
Figure 2 Nuclear P-SMAD1/5/8 and ID proteins in aMABs and eMABs. (A) IF analysis for P-SMAD1/5/8 (red) and GFP (green) (left panel) or ID
proteins (red) and GFP (green) (right panel) in GFP+ aMABs and C2C12 co-cultures on Day 0. (B) IF analysis of co-cultures as in A on Day 3 of myo-
genic differentiation. (C) WB analysis (upper panel) and quantification (lower panel) of P-SMAD1/5/8 (P-SMADs), total SMAD1/5/8 (SMADs), and
ID proteins normalized by GAPDH in C2C12, aMABs, and co-cultures on Day0and Day3of differentiation. (D) IF analysis for P-SMAD1/5/8 (red) and
GFP (green) (left panel) or IDs (red) and GFP (green) (right panel) in GFP+eMABs and C2C12 co-cultures on Day0of differentiation. (E) IF analysis of
co-cultures as in D on Day 3 of myogenic differentiation. Nuclei were stained with Hoechst (blue). (F) WB (upper panel) and quantification (lower
panel) of P-SMAD1/5/8 (P-SMADs), total SMAD1/5/8 (SMADs), and ID proteins normalized by GAPDH in C2C12, eMABs, and co-cultures on Day0
and Day 3 of differentiation. Data are representative of three independent experiments. Scale bar, 500 mm.
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Smad8 knockdown in Smad1/5-null aMAB cells significantly
improves their myogenic commitment
Smad8knockdown was attested at both mRNA andprotein levels in
Smad1/5-null aMABs transfected withSmad8-esiRNA.Smad8mRNA
progressively decreased to low levels (from 1+0.23 to 0.2+0.17
DDCt; Figure 5A) 48 h after transfection, while the protein level
decreased by 90% (Figure 5B). The differentiation of Smad1/
5-null MABs was induced in co-culture with C2C12 cells 48 h after
transfection, corresponding to the peak of silencing ofSmad8. IF ana-
lysis and MyHC levels detected by WB showed an improved differen-
tiation for Smad1/5-null MABs silenced for Smad8 (8esiRNA1/5-null
aMABs), in comparison with Smad1/5-null and wild-type aMABs
Figure 3 Interference with functional BMP signalling in aMABs and eMABs. (A,B, E) IF analysis for MyHC (red inA), Ki67 (red inB), and GFP (green)
revealed that all treatments were not able to induce myogenic differentiation (up to 10 days) in GFP+ aMABs (A). However, BMP administration
resulted in increased number of Ki67-positive cells (B and E). (C and D) IF analysis for MyHC (red) and GFP (green) of GFP+ aMABs (C) and
eMABs (D) in co-cultures with C2C12 cells pre-treated with 200 ng/ml BMP4, 100 ng/ml Noggin, or 1 mM Dorsomorphin (DM), respectively, for
48 h, and consequently subjected to myogenic differentiation for 5 days. The arrows highlight GFP+/MyHC+ double-positive myotubes. Nuclei
were stained with Hoechst (blue). (F and G) Fusion index of chimeric myotubes generated from aMABs (F) or eMABs (G) in co-culture experiments
with different treatments is reported as percentage with respect to control conditions. **P, 0.01, ***P, 0.001 vs. C. Kruskal–Wallis test per-
formed for both analyses scored P ¼ 0.0001. Scale bar, 500 mm.
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Figure4Characterization of murineSmad1/5-null aMABs and eMABs. (A) IF analysis for P-SMAD1/5/8 (red) and GFP (green) inSmad1/5-null and
WT aMABs. (B) WB analysis (left panel) and quantification (right panel) of P-SMAD1/5/8 and SMAD8 levels normalized by GAPDH inSmad1/5-null
aMABs. (C) RT-qPCR analysis of Smad8mRNA levels in Smad1/5-null aMABs. Data are expressed as fold induction compared with WT aMABs and
normalized to steady-state mRNA levels of Gapdh, Hprt, and Tbp housekeeping genes. (D) IF analysis for P-SMAD1/5/8 (red) and GFP (green) in
Smad1/5-null and WT eMABs. (E) WB analysis (left panel) and quantification (right panel) of P-SMAD1/5 and SMAD8 levels normalized by GAPDH
in Smad1/5-null eMABs. (F and G) IF analysis for MyHC (red) and GFP (green) in Smad1/5-null aMABs (F) and eMABs (G) co-cultured with C2C12
(1:1) and subjected to myogenic differentiation for 5 days. (H) Fusion index of chimeric myotubes generated from Smad1/5-null aMABs (F) or
eMABs (G) in co-culture experiments is reported as percentage with respect to WT MABs. *P, 0.05, ***P, 0.001 vs. WT. Scale bar, 500 mm.
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Figure 5 Smad8 silencing by esiRNA in aMABs. (A) RT-qPCR analysis of Smad8 transcript at 6, 24, and 48 h after Smad8 silencing in Smad1/5-null
aMABs. Data are expressed as fold expression compared with scramble treated cells and normalized to specific housekeeping genes (Gapdh,Hprt,
andTbp). Values are reported as mean+SEM. (B) WB (left panel) and quantification (right panel) of SMAD8protein levels normalized by GAPDH in
Smad1/5-null aMABs silenced forSmad8 for24,48, and72 h. (C) IF analysis for MyHC (red) and GFP (green) in WT aMAB co-cultures (left panel) and
WT aMAB silenced for Smad8 co-cultures (indicated as 8esiRNA aMABs, right panel). (D) IF analysis for MyHC (red) and GFP (green) in Smad1/5-
null aMAB co-cultures (indicated as 1/5-null aMABs, left panel) and Smad1/5-null aMABs silenced for Smad8 co-cultures (1/5-null 8esiRNA
aMABs, right panel). MyHC and GFP double-positive myotubes are highlighted with arrows. (E) Fusion index of chimeric myotubes generated
from Smad1/5-null aMABs shown in C and D is reported as percentage with respect to scramble treated aMABs. (F) WB (left panel) and quantifi-
cation (right panel) of MyHC and GFP levels normalized by TUB in WT aMABs, Smad1/5-null aMABs + Smad8esiRNA (indicated as 1/5-null
8esiRNA), and WT aMABs + Smad8esiRNA (indicated as WT 8esiRNA). (G) WB (left panel) and quantification (right panel) of MyHC and GFP
levels normalized by TUB in WT aMABs, Smad1/5-null aMABs (indicated as 1/5-null aMABs), and Smad8esiRNA-treated WT aMABs (indicated
as WT 8esiRNA). Data are representative of three independent experiments and values are expressed as mean+SD; *P, 0.05, **P, 0.01,
***P, 0.001 vs. C; $P, 0.05, $$P, 0.01, $$$P, 0.001 vs. respective controls. Scale bar, 500 mm.
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(Figure5C andD, Supplementary Figure S6B). Interestingly, the fusion
index in chimeric myotubes fromSmad8-esiRNA-treated aMABs (indi-
cated as 8esiRNA aMABs) was comparable with 8esiRNA1/5-null
aMABs (Figure 5E). This strongly suggests that Smad/8 signalling is
not involved in fusion ability ofSmad1/5-null MABs, although it posi-
tively affects myogenic protein production. Indeed, MyHC reaches
higher levels in 8esiRNA1/5-null aMAB co-cultures compared with
WTaMABsand8esiRNA aMABco-cultures(Figure5F).The90%reduc-
tion of Smad8 reached in aMABs was sufficient to increase the MyHC
protein level inco-cultureexperiments(Figure5G). Inaddition,MAPKs
were not substantially involved in this phenomenon (Supplementary
Figure6C and D). To our knowledge, this is the first report showing the
importance of SMAD8 in the myogenic differentiation ability of aMAB
cells. Finally, the results obtained strengthen the crucial role for the
BMP–SMAD pathway in the maintenance of MAB stemness.
Homozygous aMABs carrying the Smad8.LacZ do not express
Smad8 and display an enhanced myogenic commitment
Since SMAD8 is the critical factor for MAB differentiation, we iso-
lated MABs from homozygous mice carrying the Smad8.LacZ re-
porter allele (Arnold et al., 2006). We confirmed the insertion of
LacZ gene into Smad8 by PCR analysis (Supplementary Figure
S7A) and enzymatic assay (Supplementary Figure S7B) in the trans-
genic cells. We also proved that theLacZ cassette inserted into exon
2 of Smad8 disrupted the endogenous coding sequence, resulting
in the absence of SMAD8 protein (Supplementary Figure S7C). ID
proteins were decreased in Smad8.LacZMABs compared with con-
trols, and proliferation ability was reduced (Supplementary Figure
S7D). When cells were co-cultured with nLacZ C2C12 myoblasts in
differentiation medium for 5 days, Smad8.LacZ MABs were able to
form chimeric myotubes expressing MyHC, and the fusion index
highly increased in comparison with controls (Supplementary
Figure S7E–G). GFP+ Smad8.LacZ aMABs (see Materials and
methods) showed higher number of chimeric myotubes compared
with WT GFP+ aMABs in co-culture experiments (Supplementary
Figure S7H) expressing b-gal and MyHC (Supplementary Figure
S7I). In addition, C2C12-conditioned medium was able to induce
myogenic commitment in Smad8.LacZ MABs, suggesting that
they became C2C12 cell-contact independent for myogenic induc-
tion (Supplementary Figure S7J).
aMAB transplantationpartially rescuesaSGexpressionandmuscle
functionality in Sgca-null mice and contributes to muscle
regeneration in acute damage
In order to assess the in vivo relevance of SMAD perturbation in
skeletal muscle, DM-treated aMABs (aMABs+DM) were trans-
planted intramuscularly in 4 month-old Sgca-deficient (Sgca-null)
mice (Duclos et al., 1998). Upon injection into the skeletal
muscle of Sgca-null mice, GFP+ aMABs engrafted into newly
formed fibres (assessed by IF and histochemical analyses,
Supplementary Figure S8A and B). aMAB+DM cells were able to
give rise to a high number of GFP+ fibres compared with untreated
ones (Supplementary Figure S8C). Treatment with DM resulted in
an increased aSG protein rescue in aMAB-injected muscles of
Sgca-null mice (Figure 6A and B).
The treated mice were subjected to gait analysis (30 days after
cell injection) and treadmill test (15and30days after cell injection).
After 30 days, aMAB-injected mice showed an increment in func-
tional outcome when compared with sham-operated Sgca-null
mice. Intriguingly, the effect was even more pronounced after
aMABs+DM injection (Figure 7A). Sgca-null mice injected with
aMABs were able to run for significantly longer period and distance
than sham-operatedSgca-null mice (Figure7B). Pre-treatment with
DM further ameliorated the performances, as shown in Figure 7B
and C.
WefurtherperformedaMABtransplantationexperiments incrushed
TA muscles of nude mice (Supplementary Figure S9). In this acute
model of muscle regeneration, we evaluated the effect of BMP transi-
ent activation and inhibition on aMAB ability to directly contribute to
regeneration post-injuries. After 20 days from the CTX injury, the
number of GFP-positive fibres was significantly increased in TA
treated with aMABs exposed to DM and Noggin (Supplementary
Figure S9A, A′, and C). The second injury (on Day 20 from the first
injury), toevaluateafurthercycleof regeneration, resulted inthepres-
ence of GFP-positive fibres in all treated mice; however, no differences
were observed among the different groups (Supplementary Figure
S9B, B′, and C).
These results confirm that the inhibition of SMAD-mediated BMP
signalling improves the therapeutic potential of aMABs.
BMP signalling also regulates stemness of the human MAB
We expanded the studies described above to hMABs currently
involved in a clinical trial (EudraCT No. 2011-000176-33). Unlike
murine MABs, hMABs spontaneously form myotubes in differentiat-
ing conditions (Dellavalle et al., 2007). MyHC+ myotubes were
formed 15 days after the differentiation induction (Figure 8A and B).
Like murine MABs, the differentiation of hMABs was prevented as
long as SMAD1/5/8 were phosphorylated and the ID proteins were
present (Figure 8C). From the onset of differentiation, these
P-SMAD1/5/8 and ID signals disappeared (Figure 8D–F). Treatment
with Noggin or DM increased the myotube formation in differentiating
hMABs (Figure8G), confirming a comparable role of BMP signalling in
murineandhumanMABs.Asexpected, treatmentwithBMP4dropped
the fusion index of hMABs dramatically with respect to control
conditions (Figure 8H).
These results strongly point out a common and similar effect of
BMP signalling in both murine and human MABs. Furthermore,
these data suggest that perturbation of BMP signalling can improve
the myogenic potential of hMABs.
Discussion
We provide new insights regarding the previously documented
myogenic potential of MABs (Sampaolesi et al., 2003; Dellavalle
et al., 2007), which are vessel-associated cell types now used in
a phase-1 clinical trial (EudraCT #2011-000176-33) for the treat-
ment of DMD patients. Here, we investigated the involvement of
BMP and BMP–SMAD signalling in MAB myogenic commitment.
This pathway is important in several cell processes, tissues, and
organs, including cell behaviour in angiogenesis (Umans et al.,
2007; Moya et al., 2012) and cell differentiation in myogenesis
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(Velasco et al., 2008). Previously, Tagliafico et al. (2004) reported
that TGFb/BMP signalling activates smooth muscle/bone differen-
tiation programmes in embryonic MABs. We now stimulate
receptor-mediated SMAD1/5/8 phosphorylation by administering
BMP4 to embryonic and adult MABs under myogenic differentiation
conditions. This results in the blocking of MAB differentiation, likely
induced from P-SMAD1/5/8 and ID nuclear localization (Lin et al.,
2000; Clever et al., 2010), thereby promoting cell proliferation as
observed in SCs (Ono et al., 2011). When SMAD activation is pre-
vented by Noggin or DM addition, MAB cells start to differentiate.
This suggests the intriguing possibility of using the modulation of
BMP signalling, at multiple levels of the signal transduction
cascade. Indeed, DM treatment boosts MAB myogenic potential
and simultaneously improves their safety, by avoiding BMP-depend-
ent stimulation of cell proliferation. Interestingly, under our condi-
tions, SMAD1/5 are not the critical proteins responsible for MAB
cell stemness, since Smad1/5-null murine MABs are able to grow
equally as the wild-type counterparts. In addition, the differentiation
abilityof theseSmad1/5deficient MABs is not further compromised.
Smad1/5-null mice do not have skeletal muscle defects, and no
Figure 6 aMABs differentiation into aSG+ fibres. (A) IF analysis for aSG (red) and GFP (green) in Sgca-null muscles injected with GFP+ aMABs
(aMABs, middle panels) or GFP+ aMABs pretreated with DM during 48 h (aMABs+DM, lower panels). Upper panels showed sham treated
muscles. (B) Quantification of the aSG+ fibres in sham (Sgca-null) and cell-treated dystrophic muscles. **P, 0.01, ***P, 0.001 vs. Sgca-null
mice; $P, 0.05 vs. aMABs-injected mice. Scale bar, 500 mm.
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differences in muscle weight and structure were observed. This is
possibly due to a residual SMAD1/5 activity or most likely due to
the compensation by SMAD8 whose mRNA and protein levels in
Smad1/5-null pericytes were found increased. When Smad8 is
strongly downregulated (up to 90% reduction of the normal level)
in WT aMABs, cells show increased differentiation ability, resulting
in higher MyHC levels. This myogenesis induction is even further
enhanced by Smad8 knockdown in a Smad1/5-null setting.
SMAD8 represents a novel candidate target for the improvement
of MAB myogenic potential. Consistent with our data, abnormal pul-
monary vessel remodelling and smooth muscle cell aberrations were
reported inSmad8-null embryos (Huang et al.,2009). To date, no in-
formation has been available on pericyte myogenic ability from
Smad8-null mice, although adult Smad8 homozygous mutant mice
are viable and fertile (Arnold et al., 2006). We now have filled this
gap providing evidence that Smad8.LacZ MABs are able to
undergo myogenic differentiation independently by C2C12 cell
contact. This further supports our previous results obtained from
Smad8 knockdown experiments.
Pre-treating MAB cells with DM results in proliferation arrest and,
when transplanted in vivo, a better engraftment in dystrophic skel-
etal muscles. The previous beneficial effect observed in treatments
with DM of cardiotoxin-injured muscles (Ono et al., 2009, 2010)
may be explained by our work reported here. To further support
this hypothesis, we found that GFP+ myofibres were more abun-
dant in skeletal muscle injected with DM-treated GFP+ aMABs,
compared with those injected with untreated cells. The dose of
DM we used was effective in decreasing the phosphorylation of
SMAD1/5/8 (Yu et al., 2008), but appeared at the same time too
low to inhibit certain kinases (Boergermann et al., 2010; White
et al., 2013). Here, the functional read-out of the engraftment of
MABs has been convincingly demonstrated and documented,
yielding ameliorated performances by animals injected with
DM-treated MABs compared with those injected with non-treated
MABs. This was confirmed in both acute and chronic models of
muscle regeneration.
Finally, the importance of SMAD1/5/8 signalling has also been
demonstrated here in human MABs. These showed a similar ability
Figure 7 Functional analysis of aMAB-injected Scga-null mice. Gait (A) and treadmill (B) analyses of Scga-null mice injected with aMABs or aMABs
pretreated with DM for48 h (indicated as aMABs+DM). Treadmill tests were performed at two different time points (15and30days after aMABs or
aMABs+DM injections). ***P, 0.001 vs. Sgca-null Day 15; 888P, 0.01 vs. Sgca-null Day 15; $P, 0.05, $$P, 0.01, $$$P, 0.001 vs. aMABs.
Kruskal–Wallis test performed for both analysis scored P ¼ 0.0012.
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Figure8 Invitrodifferentiation of human MABs. (AandB) hMABs cultivated for15days in differentiation medium generated myotubes (bright field,
A) expressing MyHC (in red, right panel, B). (C) WB (upper panel) and quantification (lower panel) for MyHC normalized for tubulin (TUB) in hMAB
cultures on Day 0 and 15 of differentiation. ***P, 0.001 vs. d0. (D and E) IF analysis in hMAB culture on Day 0 and 10 of differentiation for
P-SMAD1/5/8 (green; upper and lower panels, D) or ID proteins (green; upper and lower panels, E). (F) WB (upper panel) and quantification
(lower panel) of P-SMAD1/5/8 (indicated as P-SMADs) normalized for total SMAD1/5/8 (SMADs) and tubulin (TUB); ID proteins were normalized
for GAPDH values. *P, 0.05 vs. d0. (G) IF analysis for MyHC (red) in hMABs cultures (C) treated for 72 h with 200 ng/ml of BMP4 (BMP4), with
100 ng/ml Noggin (Noggin) or 1 mM Dorsomorphin (DM), and consequently induced to differentiate for 15 days. Note that BMP4 completely abol-
ished hMAB differentiation into myotubes. (H) Fusion index was calculated in all different treated cultures. Nuclei were stained with Hoechst. Data
are representative of three independent experiments and values are expressed as mean+SD, represented as percentage of C. **P, 0.01, ***P,
0.001 vs. C. Kruskal–Wallis test scored P ¼ 0.0001. Scale bar, 500 mm.
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to differentiate into myotubes when treated with DM. The interesting
notion emerging from this work is the combination of human MABs
and DM to improve myogenic commitment, but further studies are
needed to evaluate the effect of DM pre-treatments in vivo. In add-
ition, novel DM-like molecules (DMH1, DMH2, DMH3, and DMH4,
and others) that are more specific and thereby less prone to
induce side effects (like inhibition of other TGFb family type I recep-
tors, a number of protein kinases, or VEGF pathways) have been
reported (Hao et al., 2010). It will be of great interest to test
whether these compounds also improve myogenic differentiation.
Materials and methods
Cell isolation and culture
All animal procedures were performed according to the guidelines
of theAnimal Welfare Committeeof KU Leuven and Belgian/European
legislation. Adult, embryonic, and cardiac mesoangioblasts (aMABs,
eMABs, and dMABs, respectively) were sorted for AP+/live staining
(Gibco-Life Technologies) as described previously (Crippa et al.,
2011; Quattrocelli et al., 2011) and transfected with Sleeping
Beauty transposon to induce GFP expression. Transfections were
carried out using a non-liposomal lipid reagent suitable for primary
cells (Effectene, Qiagen). After sorting, the GFP+ cells were cultured
on collagen-coated dishes (Sigma-Aldrich) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM)-high glucose, 20%
fetal bovine serum, supplemented with 1 mg/ml of sodium pyru-
vate, 1 IU/ml of penicillin and streptomycin, 20 mM L-glutamine,
and 1 mg/ml of non-essential amino acids. The plates were incu-
bated at 378C, 5% CO2, 5% O2, and the medium was refreshed
every 2 days.
Smad1/5-null MABs were isolated from hindlimb skeletal muscle
of 6-week-old mice (Smad1/5-null aMABs) and from the dorsal
aorta of E10.5 mouse embryos (Smad1/5-null eMAB). Homozygous
mice for floxed (fl) Smad1 (Tremblay et al., 2001) and Smad5
(Umans et al., 2003) alleles (Smad1fl/fl;Smad5fl/fl) and a RCE GFP
Cre-reporter allele (Sousa et al., 2009) (Smad1fl/fl;Smad5fl/fl;RCEfl/
fl)werematedwithaSM22-Cre-mouse(Holtwicketal.,2002) (actively
present in smooth muscle cells and pericytes; see Supplementary
Figure S6A) heterozygous for floxed Smad1 and Smad5
(SM22-Cre+/0;Smad1fl/+;Smad5fl/+) to obtain complete deletion
of the four floxed alleles of Smad1 and Smad5 in smooth muscle
cells and pericytes (SM22-Cre+/0;Smad12/2;Smad52/2;RCEfl/0) in
12.5% of the resulting offspring. Genotyping of Smad1 and Smad5
floxed vs. recombined alleles was performed as described
(Tremblay et al., 2001; Umans et al., 2007; Monteiro et al., 2008).
All mice used in these experiments have a variable mixed background
(CD1, 129/Ola, and C57BL6).
Human MABs (hMABs) were generated by F.v.T. and I.F.M.d.C.
hMABs were isolated from biopsy culture according to reported
conditions (Quattrocelli et al., 2012) and were maintained in
Iscove’s Modified Dulbecco’s Media (IMDM),10% FBS, supplemen-
ted with 1 mg/ml of sodium pyruvate, 1 IU/ml of penicillin and
streptomycin, 20 mM L-glutamine, 1 mg/ml of non-essential
amino acids, 5 ng/ml of recombinant human fibroblast growth
factor-basic (FGF-2, PeproTech, London, UK), and 1×
Insulin-Transferrin-Selenium.
For differentiation experiments, murine MABs were plated alone,
or as specified in1:1 ratio with C2C12myoblasts; in case of hMABs,
cells were always plated alone. Depending on the experiments,
cells were pre-treated (48 h) or not with 200 ng/ml of BMP4,
100 ng/ml of Noggin (R&D Systems Europe Ltd.), or 1 mM
Dorsomorphin (DM; Sigma-Aldrich), respectively, or with vehicle
as control. When confluence was reached, the differentiation was
induced by shifting medium to DMEM-high glucose supplemented
with 2% horse serum, 1 mg/ml of sodium pyruvate, and 1 IU/ml of
penicillin and streptomycin (referred to as differentiation medium).
Myogenic induction was evaluated on Day3,5, and in specific tests
on Day 10 (murine MAB spontaneous differentiation, Figure 3A) or
on Day 14 (hMAB myogenic differentiation, Figure 8A and B).
Smad8 knockdown
In order to efficiently knockdown murine Smad8, endoribo-
nuclease-prepared siRNAs against Smad8 (in fact named Smad9
esiRNAs; Sigma-Aldrich) were applied following the manufacturer’s
instructions. Briefly, aMABs and Smad1/5-null aMABs were trans-
fected with mouse Smad9 esiRNA using Lipofectamine-2000 and
Opti-MEM. At different time points after transfection, cells were
lysed for RNA extraction or western blot (WB) analysis. RNA Mini
Kit was used for RNA isolation, and genomic DNA traces were
removed with Turbo DNase, following manufacturer’s instructions.
One microgram of RNA was reverse-transcribed with the
SuperScript III kit. The resulting cDNA (1:4 dilution) was transferred
in a 384-well plate pre-filled with 250 nM primers (Smad8-Fw:
CAGCATCTTTGTCCAGAGCC, Smad8-Rev: AAAGCTCATCCGAATCGT
GC;glyceraldehyde-3-phosphate dehydrogenase,Gapdh-Fw: TGGT
GAAGGTCGGTGTGAAC, Gapdh-Rev: GCTCCTGGAAGATGGTGATGG;
TATA-box binding protein, TBP-Fw: CAAACCCAGAATTGTTCTCCTT,
TBP-Rev: ATGTGGTCTTCCTGAATCCCT;hypoxanthineguaninephos-
phoribosyl transferase, HPRT-Fw: TGGATACAGGCCAGACTTTGTT,
HPRT-Rev: CAGATTCAACTTGCGCTCATC) and Platinum Sybr Green
Mix to a final volume of 10 ml/well. The RT-qPCR was performed
for 40 cycles (958C, 15 sec; 588C, 45 sec) and read on a ViiA 7
qPCR plate reader.
In vivo experiments
Intramuscular injections of 2 × 105 GFP+ aMAB or aMAB cells
pre-treated for 48 h with 5 mM Dorsomorphin (DM-aMABs) were
performed in Sgca-null (C57/BL6 background) dystrophic mice
(4-month-old, n ¼ 8 for each group), which were generated by the
group of K.P. Campbell (University of Iowa, IA, USA) (Duclos et al.,
1998). During the entire treatment, mice were maintained with
cyclosporine (Sandimmune Cyclosporine, Novartis; 10 mg/kg).
Functional assays were performed on the same mice 15 and 30
days post-injection and compared to sham-operated mice (saline so-
lution injected mice) (Hampton et al., 2011; Consalvi et al., 2013).
The micewere introduced to the treadmill belt and testing conditions
before the actual recordings (motor speed set to zero, for 5 min).
Later on, the motor speed was set to 10 m/min, with a 1 m/min in-
crease and an uphill inclination of 108, till exhaustion and .10s
stop. For the gait analysis test, as previously described (Hamers
et al., 2006), the animals were placed in a corridor (1 m long and
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8.5 cm wide) and allowed to move freely across the walkway. Tracks
with a straight walking direction and without any interruption or
hesitation were acquired (5 runs from each animal). Values from
the analysed tracks for each mouse were averaged and used for
data processing. After sacrificing the mice, tibialis anterior (TA),
gastrocnemius (GSN), and quadriceps (QD) muscles were excised
and stored at 2808C for further analysis.
Intramuscular injections of 2× 105 GFP+ aMAB or aMAB cells pre-
treated for 48 h with 200 ng/ml of BMP4, 100 ng/ml of Noggin, or
5 mM Dorsomorphin (as previously described) were performed in
6-week-old male athymic nude mice (NMRI, nu/nu, Charles River;
n¼ 6 for each group). Mice received a 10 mM solution of cardiotoxin
(CTX,NajaMossambicaMossambica, Sigma-Aldrich) in the TA of each
hind limbat48 hbefore the cell injection and again after20days.After
the in vivo experiments, the mice were sacrificed by cervical disloca-
tion and TA muscles were processed for histological analysis.
Immunofluorescence analysis
Tissues (7 mm) and cells were fixed with 4% paraformaldehyde
(PFA, Polysciences Europe GmbH) in PBS and permeabilized with
0.2% Triton X-100 in PBS containing 1% (w/v) bovine serum
albumin (BSA). A blocking solution containing donkey serum
(1:10 dilution in PBS; VWR) was applied, and primary antibodies
(reported hereafter) were incubated overnight in PBS supplemen-
ted with 1% BSA. Secondary Alexa Fluor donkey antibodies were
diluted at 4 mg/ml in PBS supplemented with 1% BSA, and the
nuclei were counterstained with 10 mg/ml Hoechst. Fluor Save
reagent (Millipore, Chemicon) was used as mounting medium.
Images were acquired using an Eclipse Ti inverted microscope
(Nikon). The fusion index (e.g. the number of myotube nuclei vs.
the total number of nuclei) for hMAB cultures or the percentage
of nuclei in GFP+ myotubes vs. the total number of nuclei for all
co-cultures was calculated for a minimum of four random fields in
each condition (n ¼ 3).
The primary antibodies and their dilutions were as follows: 1:300
rabbit anti-GFP (Life Technologies) or 1:500 goat anti-GFP (Abcam; de-
pending on the specific use for IF or WB analyses and on the combin-
ation with other antibodies), 1:3 mouse anti-MyHC (Developmental
Studies Hybridoma Bank, DSHB, clone MF20), 1:1000 rabbit anti-
P-SMAD1/5/8 or rabbit anti-P-SMAD1/5 (Cell Signalling), 1:200
rabbit anti-ID1 (Santa Cruz Biotechnology).
Immunohistochemistry
Sections (7 mm) were pre-incubated in peroxidase blocking solu-
tion, followed by an overnight incubation at 48C with 1:500 goat
anti-GFP (Abcam). The sections were then washed and incubated
with 1:750 biotinylated anti-goat antibody (VECTOR), and finally
with 1:100 Streptavidin-HRP (VECTOR). The antibody staining
was visualized with 0.05% DAB (Sigma-Aldrich) and sections
were mounted with Fluor Save reagent (Millipore, Chemicon).
Lacz staining
Smad8.LacZ aMABs and nLacZ C2C12 cells were fixed for 15–
30 min in PFA and washed three times for 15 min with NP40 and
deoxycholate. The LacZ staining was performed at 378C using the
X-gal solution (Sigma-Aldrich), and the intensity of the signal was
monitored under inverted microscope (1–2 h).
Western blotting
Western blotting (WB) analysis was performed on lysates from
tissue or cells in RIPA buffer (Sigma-Aldrich) supplemented with
10 mM Sodium Fluoride, 0.5 mM Sodium Orthovanadate, 1:100
Protease Inhibitor Cocktail, and 1 mM Phenylmethylsulfonyl
Fluoride (PMSF). Equal amounts of protein (40 mg) were heat-
denatured in sample-loading buffer (50 mM Tris–HCl, pH 6.8,
100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol),
resolved by SDS-polyacrylamide gel electrophoresis, and then
transferred to nitrocellulose membranes (Protran, Nitrocellulose
membrane, Sigma-Aldrich). The filters were blocked with
Tris-buffered saline (TBS) containing 0.05% Tween and 5%
non-fat dry milk (Sigma-Aldrich) and then incubated overnight
with the indicated dilutions of different primary antibodies: 1:10
mouse anti-MF20 (Developmental Studies Hybridoma Bank,
DSHB), 1:1000 rabbit anti-P-SMAD1/5/8 (hereafter indicated as
anti-P-SMADs) or 1:1000 rabbit anti-P-SMAD1/5 (Cell Signalling),
1:500 rabbit SMAD1/5/8 (hereafter indicated as anti-SMADs;
Thermo Fisher Scientific Inc.), 1:100 rabbit anti-ID1 (Santa Cruz
Biotechnology),1:100goat anti-SMAD8 (Sigma Aldrich). All second-
ary horseradish peroxidase (HRP)-conjugated antibodies (Santa Cruz
Biotechnology) were diluted 1:5000 in TBS-Tween and 2.5% non-fat
dry milk (Sigma-Aldrich). After incubation with SuperSignal Dura
Chemiluminescence substrate (Thermo Scientific), the polypeptide
bands were detected with GelDoc chemiluminescence detection
system (BioRad). Quantitation was performed on gels loaded and
blotted in parallel, and relative densitometry was obtained by
normalizing the protein band vs. background and housekeeping
protein (Glyceraldehyde 3-phosphate dehydrogenase, GAPDH,
Sigma-Aldrich; Tubulin beta, TUB clone KMX-1, Millipore, Merck
KGaA) using the QuantityOne software (BioRad).
RT-qPCR
Conventional RT-qPCR analysis for the mRNA levels of SM22 in
different cell types has been performed using primers and following
conditions described previously (Sohni et al., 2012). LacZ gene ex-
pression fromSmad8.LacZmice was established with the following
primers: LacZ-Fw: TTGAAAATGGTCTGCTGCTG, LacZ-Rev: TATTGGC
TTCATCCACCACA. PCR products (expected as an amplified fragment
of 226 bp) were separated on 2% agarose gels and visualized with
SybrSafe (Life Technologies) on a GelDoc UV detection system
(BioRad).
Statistical analysis
All results were expressed as mean+SD, with the exception of
gene expression (mean+SEM). Representative WBs were selected
from independent experiments. When data distribution approxi-
mated normality and two groups were compared, a Student’s
t-test was used. When three or more groups were compared, a
two-way ANOVA was used. In case of non-normal distribution of
the data pools, such as for statistical comparison of the differences
between percentage values, a Kruskal–Wallis one-way analysis of
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variance by rank test was used. All statistical tests were performed
via Prism software (GraphPad).
Supplementary material
Supplementary material is available at Journal of Molecular Cell
Biology online.
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